Phase 3 Canines Lymphoma B Trial ( what to expect), page-99

Yes Jakjazz , PAA has one , the same PR agency for 7 years , Monsoon, I have yet to see a release that warrants any accolade,

PAA has been covering significant ground , The Tablets being one very significant Milestone should have had some care associated with their announcement of delivery...

Someone needs to stand aside or fall on their sword , messaging is a train wreck , pure and simple .. below are two years of positive announcements,, Question 1 for the AGM: why didn't the BOD see fit to monitor Market Messaging and the catastrophic effect it had on the value of Pharmaust?
Blind Freddy could look at the Volume and see the company is lacking Market Awareness...

PAAPharmaust Ltd

April 2022
19th	PharmAust Receives $708k R&D Tax Incentive Refund
8th	PAA appoints trial manager & receives $200k from FightMND
March 2022
31st	Notification of cessation of securities - PAA
15th	MPL manufactured and tableting commenced
February 2022
23rd	Preliminary MPL antiviral leukaemia preclinical WEHI results
21st	Key Appointment to Progress MPL COVID-19 Clinical Trial
18th	Appendix 4D & Half Year Report
16th	Epichem Confirms Effectiveness of OHD E-Waste Project
3rd	Resignation of Epichem CEO
2nd	Update on Manufacture of MPL & Tablets for Clinical Trials
January 2022
31st	Appendix 4C and Quarterly Update

December 2021
15th	Epichem Awarded Contract Extension from DNDi
13th	Shareholder Update - Progress and Strategy
1st	Demonstration batch of smaller size MPL tablets completed
November 2021
17th	MND & COVID-19 Phase 1 Clinical Trials On-Track
16th	Cleansing Notice
16th	Application for quotation of securities - PAA
15th	Canine phase 2b cancer trial expands to New Zealand
12th	JobKeeper Payment Notification
9th	Change of Director's Interest Notice x 4
9th	PAAO Top 20 Holders & Distribution Schedule
9th	Application for quotation of securities - PAA
5th	Closure of Entitlement Offer
October 2021
29th	Appendix 4C and Quarterly Update
22nd	Results of Annual General Meeting
21st	AGM Presentation
21st	MPL Manufacturing and Human Trials Update
18th	Following Extension of Survival, PAA Prepares Phase 3 Trial
1st	Proposed issue of securities - PAA
1st	Prospectus
1st	Entitlement Options Offer
September 2021
17th	Notice of Annual General Meeting/Proxy Form
17th	Letter to shareholders re AGM
9th	Broker Briefing Presentation Tech & Biotech Investor Webinar
7th	Broker Briefing Investor Webinar
August 2021
31st	Epichem Completes Final Loan Repayment
24th	Change of Director's Interest Notice
24th	Application for quotation of securities - PAA
18th	Appendix 4G & Corporate Governance Statement
18th	Appendix 4E & Full Year Statutory Accounts
3rd	Epichem Completes Build of OHD Benchtop Flow Reactor
July 2021
30th	Virtual Investor Briefing
28th	Appendix 4C and Quarterly Update
26th	Monepantel and monepantel sulfone COVID-19 anti-viral update
22nd	PharmAust files patent for monepantel in viral diseases
12th	PharmAust and WEHI to Investigate HTLV-1 Viral Infections
9th	Science Week Conference Presentation
7th	PharmAust establishes monepantel GMP tablet stability
June 2021
28th	Phase IIb Dog Trial Achieves Interim Clinical Endpoints
2nd	PharmAust receives ethics approval for Phase I trial in MND
May 2021
14th	Dr Kim Agnew appointed Principal Investigator of dog trial
April 2021
29th	Appendix 4C and Quarterly Update
27th	Phase IIb Canine Trial Identifies Therapeutic Window for MPL
21st	Epichem OHD Presentation - Waste to Fuels Technology
8th	PharmAust Receives $750k R&D Tax Incentive Refund
7th	Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
6th	Trading Halt
6th	Pause in Trading
March 2021
30th	Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs
29th	Epichem business support program for advanced technologies
23rd	Licensing Agreement to Develop Waste to Fuels Technology
February 2021
26th	Appendix 4D & Half Year Report
15th	Update on Phase IIb Clinical Trial recruitment
10th	Update on COVID-19 testing in the Netherlands
5th	Virtual Investor Briefing
January 2021
27th	Appendix 4C and Quarterly Update
22nd	Epichem Awarded $200K WasteSorted e-Waste Grant
8th	Leiden University Medical Centre Monepantel COVID-19 Testing
5th	PAA & ONJCRI to Continue MPL Pre-clinical Investigations

December 2020
23rd	PAA Commences Manufacture of GMP-Grade MPL for Human Trials
22nd	PharmAust to Commence Phase IIb Dog Cancer Trial
21st	Epichem Awarded Contract Extension from DNDi
4th	Appendix 2A & s708 notice (exercise of options)
November 2020
5th	Results of Annual General Meeting
5th	AGM Shareholder Presentation
October 2020
29th	Appendix 4C and Quarterly Update
21st	Appendix 2A & s708 notice (exercise of employee options)
21st	Appendix 3G
12th	Appendix 2A & s708 notice
2nd	Notice of Annual General Meeting/Proxy Form
September 2020
29th	ONJCRI Evaluates Monepantel Anti-Cancer Mechanism
28th	Clarification statement
24th	PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 Test
21st	PAA awarded grant for Phase I trial in Motor Neurone Disease
18th	Appendix 4G & Corporate Governance Statement
18th	Annual Report
14th	PharmAust Shareholder Update
9th	Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed
9th	Elanco Option Update
7th	Trading Halt
1st	Epichem in partnership to develop waste into fuel technology
August 2020
31st	Appendix 2A & s708 notice (exercise of employee options)
31st	Appendix 4E & Preliminary Final Report
25th	Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells